GlassScriptPhysician profile
Amanda G Appling
NPI 1386938611
$19,097.20
in general payments reported to CMS, 2019-2025
36 companies · $2,933 in 2025
The $2,933 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,387 · 2022: $3,673 · 2023: $4,190 · 2024: $4,914 · 2025: $2,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $1,080 · Education: $129 · Travel and Lodging: $32.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,796.41 |
| Consulting Fee | $1,080.00 |
| Education | $128.55 |
| Travel and Lodging | $32.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,449.19 | 2021-2025 | |
| Ucb, INC. | $3,052.21 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $2,317.48 | 2021-2025 | Enbrel, Evenity, Tavneos |
| Janssen Biotech, INC. | $1,616.01 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $1,132.09 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $1,005.20 | 2022-2025 | Acthar |
| Pfizer INC. | $849.23 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $802.20 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $715.91 | 2021-2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $603.63 | 2021-2024 | Ofev |
| Genzyme Corporation | $419.57 | 2021-2025 | |
| Horizon Therapeutics Plc | $402.67 | 2021-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $361.14 | 2021-2025 | Orencia |
| Sobi, INC | $323.21 | 2022-2025 | |
| Glaxosmithkline, LLC. | $303.09 | 2021-2025 | Benlysta |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $235.85 | 2021-2023 | Actemra |
| Aurinia Pharma U.S., INC. | $228.63 | 2022-2024 | Lupkynis |
| Ani Pharmaceuticals, INC. | $222.26 | 2022-2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $184.00 | 2021-2023 | |
| Radius Health, INC. | $135.08 | 2022-2024 | Tymlos |
| Organon LLC | $132.04 | 2023-2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $112.68 | 2024 | |
| Sandoz INC. | $88.98 | 2023-2025 | Hyrimoz |
| Invivyd INC | $57.71 | 2025 | Pemgarda |
| Boston Scientific Corporation | $52.47 | 2024-2025 | Varithena Administration Pack, Watchman Flx |
| Baxter Healthcare | $44.19 | 2021 | |
| Fresenius Kabi USA, LLC | $42.44 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.01 | 2021 | |
| Antares Pharma, INC. | $32.80 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $32.34 | 2023 | Arcalyst |
| Octapharma USA, INC. | $24.40 | 2025 | Octagam Immune Globulin (Human) |
| Pacira Pharmaceuticals Incorporated | $20.74 | 2024 | Zilretta |
| Tonix Medicines, INC. | $17.47 | 2025 | Tonmya |
| Ibsa Pharma INC. | $16.82 | 2021 | |
| Endo USA, INC. | $16.06 | 2025 | Xiaflex |
| Kiniksa Pharmaceuticals International, Plc | $13.40 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Appling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.